Related Experiment Videos
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells
F A Fornari1, J K Randolph, J C Yalowich
1Department of Medicine, Medical College of Virginia, Richmond 23298.
Abstract:
The capacity of doxorubicin to inhibit topoisomerase II in the MCF-7 breast tumor cell line is supported by the induction of protein-associated single-strand breaks in DNA, as well as by interference with the decatenation activity of nuclear extracts. Doxorubicin also produces non-protein-associated DNA strand breaks (at a supraclinical concentration of 5 microM), which may indicate damage mediated via the generation of free radicals. However, no strand breaks are detected in DNA of MCF-7 cells at the IC50 for doxorubicin (approximately 0.1 microM). At doxorubicin concentrations of 0.05, 0.1, and 0.5 microM, at which growth is inhibited by approximately 15, 50, and 75%, respectively, doxorubicin interferes with radiation-induced unwinding of DNA; doxorubicin also produces a concentration-dependent inhibition of DNA synthesis that corresponds closely to growth inhibition. These studies suggest that DNA strand breaks fail to fully account for the antiproliferative activity of doxorubicin in the MCF-7 breast tumor cell line. Compromised DNA synthesis associated with interference with DNA unwinding may contribute to growth inhibition in MCF-7 cells exposed to doxorubicin.
Insights
Doxorubicin inhibits breast cancer cell growth by interfering with DNA synthesis and unwinding, not solely through DNA strand breaks. These findings offer insights into doxorubicin
Area of Science:
- Molecular Biology
- Cancer Research
- Pharmacology
Background:
- Doxorubicin is a widely used chemotherapy agent.
- Its mechanism of action involves DNA damage.
- Understanding its precise effects on cancer cells is crucial.
Purpose of the Study:
- To investigate the role of DNA strand breaks in doxorubicin's antiproliferative effects.
- To explore other potential mechanisms of growth inhibition by doxorubicin.
- To examine doxorubicin's impact on DNA synthesis and unwinding in MCF-7 breast tumor cells.
Main Methods:
- Assessing protein-associated and non-protein-associated DNA strand breaks.
- Evaluating the effect of doxorubicin on topoisomerase II activity.
- Measuring DNA synthesis inhibition and interference with radiation-induced DNA unwinding.
- Correlating these effects with cell growth inhibition at various doxorubicin concentrations.
Main Results:
- Doxorubicin induces protein-associated DNA strand breaks and inhibits topoisomerase II decatenation activity.
- No DNA strand breaks were detected at the IC50 concentration (0.1 microM).
- Doxorubicin interfered with DNA unwinding and inhibited DNA synthesis in a dose-dependent manner, correlating with growth inhibition.
Conclusions:
- DNA strand breaks alone do not fully explain doxorubicin's antiproliferative activity in MCF-7 cells.
- Inhibition of DNA synthesis and interference with DNA unwinding are significant contributors to doxorubicin-induced growth inhibition.
- These findings highlight the complex mechanisms underlying doxorubicin's efficacy in breast cancer treatment.